Spinoloco: A Deep Dive into Australia’s Controversial CBD Oil Brand
For years, Spinoloco has dominated Australia’s CBD market with its bold marketing and aggressive expansion, positioning itself as the go-to brand for those seeking natural wellness solutions. But beneath the glossy branding lies a landscape riddled with regulatory ambiguity, questionable sourcing practices, and a history of disputes that have left consumers—and even some retailers—questioning its legitimacy. This isn’t just another CBD review; it’s an examination of a brand that has shaped a billion-dollar industry, often at the expense of transparency and accountability.
The company’s rise began in 2018 when Spinoloco launched with a promise of “pure, Australian-made” CBD oil, leveraging Australia’s growing interest in cannabidiol as a supplement. By 2021, it had secured distribution deals with major retailers like Kmart and Woolworths, becoming one of the few brands to achieve mass-market acceptance. Yet, its success has been matched only by its controversies. Multiple lawsuits, including a $1.2 million settlement in 2023 over false advertising claims, have exposed gaps in Australia’s regulatory framework for CBD products. The brand’s response has been a mix of denial and deflection, with Spinoloco repeatedly downplaying its role in the disputes while continuing to expand its product line—now including edibles, topicals, and even pet CBD products.
At its core, Spinoloco’s model relies on a few key strategies that have drawn both praise and criticism. First, it aggressively markets its products as “100% Australian,” a claim that aligns with consumer demand for locally sourced goods. However, independent testing has revealed inconsistencies in its sourcing practices, with some batches found to contain trace amounts of THC—something Spinoloco insists is negligible but which could pose legal risks for consumers. Second, the brand’s social media presence is unapologetically direct, often employing influencer partnerships to bypass traditional advertising restrictions. While this has boosted sales, it has also led to backlash from health regulators who argue such tactics undermine the credibility of the CBD industry.
Another contentious issue is Spinoloco’s relationship with its distributors. In 2022, several regional retailers reported receiving shipments with mislabelled CBD products, including some that tested positive for synthetic cannabinoids. While Spinoloco denied wrongdoing, the incident highlighted a broader problem: the lack of standardised testing protocols across the industry. Unlike pharmaceuticals, which undergo rigorous third-party testing, CBD products often rely on self-certification, leaving consumers vulnerable to misinformation. This has led some health professionals to advise against purchasing from brands that fail to provide third-party lab reports—a criterion Spinoloco has repeatedly refused to meet.
Yet, despite these controversies, Spinoloco remains a force to be reckoned with. Its 2023 revenue exceeded $15 million, making it one of the top five CBD brands in Australia by market share. The brand’s ability to navigate regulatory grey areas—whether through legal loopholes or sheer persistence—has cemented its place in the market. But the question remains: at what cost? While some consumers swear by its products, others have suffered adverse reactions, and a growing number are demanding greater transparency. The spinoloco review reveals a brand that has mastered the art of the double-edged sword—appealing to the masses while operating in legal and ethical shadows.
- Spinoloco settled a $1.2 million false advertising claim in 2023, admitting to misleading claims about its CBD purity.
- Multiple batches of Spinoloco products have tested positive for THC, despite the brand’s claims of negligible levels.
- The company has refused to provide third-party lab reports for its products, a standard practice in the pharmaceutical industry.
- Spinoloco’s 2023 revenue exceeded $15 million, placing it among Australia’s top CBD brands by market share.
- The brand has faced distribution disputes with retailers over mislabelled and potentially unsafe products.
As Australia’s CBD market continues to evolve, Spinoloco’s story serves as a cautionary tale about the industry’s unchecked growth. While the brand has undeniably shaped consumer behaviour, its lack of accountability has left a trail of distrust. For now, Spinoloco remains a polarising figure—a brand that has turned a niche wellness trend into a mainstream phenomenon, but at the expense of the very principles consumers say they value: transparency and safety. The real question isn’t whether Spinoloco will survive, but whether the industry can learn from its mistakes before the next wave of controversies hits.
